Marker Therapeutics(MRKR)
$0.87-0.03 (-3.33%)
MRKR
Marker Therapeutics financials statements
$0.87
At close:-0.03 (-3.33%)
Want to see MRKR full AI Analyst Report?
Marker Therapeutics (MRKR) Ratios
609 Followers
Marker Therapeutics Ratios
MRKR's free cash flow for Q2 2026 was $-3.72M. For the 2026 fiscal year, MRKR's free cash flow was increased by $0.00 and operating cash flow was $-3.72M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.39 | 6.36 | 5.57 | 2.14 | 3.56 |
| Quick Ratio | 8.39 | 6.36 | 5.89 | 2.14 | 3.56 |
| Cash Ratio | 7.07 | 5.54 | 4.91 | 1.51 | 3.28 |
| Solvency Ratio | -5.35 | -3.10 | -1.77 | -1.83 | -1.60 |
| Operating Cash Flow Ratio | -5.28 | -3.15 | -5.35 | -3.47 | -2.11 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 16.80M | $ 18.56M | $ 14.05M | $ 1.80M | $ 21.83M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.22 | 0.17 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.39 | 0.27 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.28 | 0.21 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.14 | 1.19 | 1.22 | 1.76 | 1.55 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.91 | 1.55 |
| Net Debt to EBITDA | 1.29 | 1.80 | 1.28 | 0.25 | 0.79 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -104.33% | -214.60% | -240.64% | -154.70% |
| EBIT Margin | 0.00% | -162.06% | -440.37% | -563.28% | -3372.68% |
| EBITDA Margin | 0.00% | -162.06% | -356.14% | -483.90% | -3117.98% |
| Operating Profit Margin | 0.00% | -168.69% | -440.37% | -563.28% | -3179.32% |
| Pretax Profit Margin | 0.00% | -162.06% | -424.09% | -562.85% | -3372.68% |
| Net Profit Margin | 0.00% | -162.82% | -248.76% | -851.87% | -3372.68% |
| Continuous Operations Profit Margin | 0.00% | -162.82% | -424.20% | -562.85% | -3372.68% |
| Net Income Per EBT | 99.88% | 100.47% | 58.66% | 151.35% | 100.00% |
| EBT Per EBIT | 94.48% | 96.07% | 96.30% | 99.92% | 106.08% |
| Return on Assets (ROA) | -63.78% | -48.73% | -48.09% | -86.95% | -61.46% |
| Return on Equity (ROE) | -72.42% | -57.82% | -58.61% | -152.70% | -95.21% |
| Return on Capital Employed (ROCE) | -76.74% | -59.91% | -103.76% | -74.29% | -71.47% |
| Return on Invested Capital (ROIC) | -76.65% | -59.91% | -103.76% | -72.71% | -70.68% |
| Return on Tangible Assets | -63.78% | -48.73% | -48.09% | -86.95% | -61.46% |
| Earnings Yield | -53.32% | -38.43% | -17.00% | -134.79% | -57.61% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 2.81 | 3.22 | 1.46 | 5239.28 |
| Payables Turnover | 0.00 | 12.63 | 10.84 | 10.87 | 0.61 |
| Inventory Turnover | 0.00 | 0.00 | -10.54 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.20 | 0.06 |
| Asset Turnover | 0.00 | 0.30 | 0.19 | 0.10 | 0.02 |
| Working Capital Turnover Ratio | 0.00 | 0.40 | 0.29 | 0.17 | 0.05 |
| Cash Conversion Cycle | 0.00 | 101.07 | 45.00 | 215.95 | -593.60 |
| Days of Sales Outstanding | 0.00 | 129.96 | 113.30 | 249.53 | 0.07 |
| Days of Inventory Outstanding | 0.00 | 0.00 | -34.62 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 28.89 | 33.67 | 33.58 | 593.67 |
| Operating Cycle | 0.00 | 129.96 | 78.68 | 249.53 | 0.07 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.78 | -1.21 | -1.87 | -3.23 | -3.57 |
| Free Cash Flow Per Share | -0.78 | -1.21 | -1.87 | -3.23 | -3.97 |
| Dividend Paid and CapEx Coverage Ratio | -12014081.00 | -2727581.00 | 0.00 | -8990717.67 | -8.71 |
| Capital Expenditure Coverage Ratio | -12014081.00 | -2727581.00 | 0.00 | -8990717.67 | -8.71 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -3.54 | -2.30 |
| Operating Cash Flow to Sales Ratio | 0.00 | -1.66 | -4.97 | -7.68 | -21.97 |
| Free Cash Flow Yield | -52.67% | -39.07% | -33.93% | -121.47% | -41.83% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.89 | -2.61 | -5.88 | -0.74 | -1.74 |
| Price-to-Sales (P/S) Ratio | 0.00 | 4.24 | 14.63 | 6.32 | 58.55 |
| Price-to-Book (P/B) Ratio | 1.36 | 1.50 | 3.45 | 1.13 | 1.65 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.90 | -2.56 | -2.95 | -0.82 | -2.39 |
| Price-to-Operating Cash Flow Ratio | -1.90 | -2.56 | -2.95 | -0.82 | -2.66 |
| Price-to-Earnings Growth (PEG) Ratio | 0.06 | 0.07 | 0.13 | 0.02 | 0.17 |
| Enterprise Value Multiple | -0.54 | -0.82 | -2.83 | -1.06 | -1.09 |
| Enterprise Value | 6.74M | 8.74M | 33.34M | 18.04M | 42.22M |
| EV to EBITDA | -0.54 | -0.82 | -2.83 | -1.06 | -1.09 |
| EV to Sales | 0.00 | 1.33 | 10.07 | 5.13 | 34.00 |
| EV to Free Cash Flow | -0.56 | -0.80 | -2.03 | -0.67 | -1.39 |
| EV to Operating Cash Flow | -0.56 | -0.80 | -2.03 | -0.67 | -1.55 |
| Tangible Book Value Per Share | 1.10 | 2.07 | 1.60 | 2.35 | 5.75 |
| Shareholders’ Equity Per Share | 1.10 | 2.07 | 1.60 | 2.35 | 5.75 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | -0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.73 | 0.38 | 0.42 | 0.16 |
| Net Income Per Share | -0.79 | -1.20 | -0.94 | -3.58 | -5.47 |
| Tax Burden | 1.00 | 1.00 | 0.59 | 1.51 | 1.00 |
| Interest Burden | 0.98 | 1.00 | 0.96 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 2.04 | 3.15 | 3.41 | 22.38 |
| SG&A to Revenue | 0.00 | 0.64 | 2.26 | 3.23 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.04 | 0.26 | 0.00 | 4.80 |
| Income Quality | 0.99 | 1.02 | 1.17 | 1.36 | 0.65 |
Currency in USD
